clinicalomicsprowebdirectory
News & Features
Topics
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Magazine
Multimedia
Webinars
eBooks
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Search
Advertise
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Lead Generation Campaigns
Email Nurture Campaigns
Custom Content Solutions
About Us
Contact Us
Mary Ann Liebert Publishers
Create a Free Account
Log In
Clinical OMICs – Molecular Diagnostics in Precision Medicine
News & Features
Bioinformatics
Largest Study to Date of COVID-19 Susceptibility Launched
Bioinformatics
Prototype Tool Leverages AI to Predict Which COVID-19 Patients Most Likely…
Precision Medicine
Germline Mutations in Cancer Patients Predict Disease Progression
Oncology
Ovarian Cancer Cells’ Dependence on Fat Suggests New Therapeutic Target
Precision Medicine
COVID-19 Patients May Carry Virus after Symptoms Have Resolved
Topics
All
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Bioinformatics
Largest Study to Date of COVID-19 Susceptibility Launched
Bioinformatics
Prototype Tool Leverages AI to Predict Which COVID-19 Patients Most Likely…
Precision Medicine
Germline Mutations in Cancer Patients Predict Disease Progression
Oncology
Ovarian Cancer Cells’ Dependence on Fat Suggests New Therapeutic Target
Magazine
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 2
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 1
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 6
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 5
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 4
Multimedia
All
Webinars
eBooks
eBooks
Clinical Research in a Real-Time Sequencing Age
Precision Medicine
From Bench to Clinic—The Potential of New Sequencing Tools
Precision Medicine
Mainstreaming Precision Oncology
eBooks
Better Understanding of Post-Translation Modifications Driving Innovation
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Home
Precision Medicine
Business
Business
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
News Briefs
Lloyd Sanders Named New CEO of Epic Sciences
March 26, 2019
Business
10 Leading Immuno-Oncology Startups
March 25, 2019
Business
Mammoth Competition: Feng Zhang, Partners Launch CRISPR Dx Company
March 22, 2019
Business
Viome, Helomics Partner on Personalized Ovarian Cancer Treatments
March 21, 2019
Business
Ambry and My Gene Counsel Team Up on Tests to Confirm...
March 19, 2019
Business
UK Commits £45M Toward Capacity Expansion at EMBL-EBI
March 15, 2019
Business
Myriad Genetics Gets Medicare Coverage for myPath Melanoma Test
March 14, 2019
Business
Lucence, Stanford Researcher to Develop AI Algorithms for Liver Cancer Treatment
March 14, 2019
Business
BGI Genomics to Commercialize Natera’s Signatera Assay in China
March 13, 2019
Business
Biocartis, BMS to Partner on CDx for mCRC Immunotherapy Combination
March 12, 2019
Load more
Scroll Up
We use cookies to give you a better experience on clinicalomics.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
![Myriad Genetics has received a final local coverage determination for its myPath Melanoma test from the Medicare Administrative Contractor Palmetto GBA MolDx. [Myriad Genetics]](https://www.clinicalomics.com/wp-content/uploads/2019/03/2189-324x160.jpeg "Myriad Genetics Gets Medicare Coverage for myPath Melanoma Test")
![Lucence Diagnostics will partner with a Stanford University researcher to develop AI algorithms designed to improve the diagnosis and treatment of liver cancer. [Lucence Diagnostics]](https://www.clinicalomics.com/wp-content/uploads/2019/03/2187-324x160.jpeg "Lucence, Stanford Researcher to Develop AI Algorithms for Liver Cancer Treatment")
![Biocartis will partner with Bristol-Myers Squibb (BMS) to develop a companion diagnostic for the pharma giant’s immuno-oncology therapies based on the Belgian molecular diagnostics developer’s Idylla MSI test. [Biocartis]](https://www.clinicalomics.com/wp-content/uploads/2019/03/2185-324x160.jpeg "Biocartis, BMS to Partner on CDx for mCRC Immunotherapy Combination")
